Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years

Liver Transplantation

Volumn 7, Issue 7, 2001, Pages 623-630

  Jain, Ashok ^a   Demetris, Anthony Jake ^a   Kashyap, Randeep ^a   Blakomer, Karen ^a   Ruppert, Kris ^b   Khan, Akhtar ^a   Rohal, Susan ^a   Starzl, Thomas E ^a   Fung, John J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Department of Health Services Research and Policy

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MEPREDNISONE; STEROID; TACROLIMUS;

ADULT; AGE; ALLOGRAFT; ARTERY DISEASE; ARTICLE; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENCY; DRUG USE; EVALUATION; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PATHOGENESIS; PREDICTION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; RISK FACTOR; STATISTICAL ANALYSIS; TIME;

EID: 0034927968     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.25364     Document Type: Article

References (55)

1. Liver transplantation with use of cyclosporine A and prednisone
2. Experience in 1,000 liver transplants under cyclosporine-steroid therapy: A survival report
3. Chronic rejection of the liver allograft
4. Vanishing bile-duct syndrome following liver transplantation-Is it reversible?
5. Chronic allograft rejection
6. Incidence and outcome of chronic rejection in CyA- and FK506-treated patients
7. Combination immunosuppression with azathioprine reduces the incidence of ductopenic rejection and vanishing bile duct syndrome after liver transplantation
8. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
9. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation
10. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation
11. Randomised trialomania? The multicentre liver transplant trials of tacrolimus
12. Long-term survival after liver transplantation in 4000 consecutive patients at a single center
13. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications
14. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: Benefits and pitfalls
15. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: A report of the US Multicenter Liver Study Group
16. FK 506 used as rescue therapy for human liver allograft recipients
17. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy-A clinicopathologic study of 96 patients
18. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression
19. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant
20. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506
21. One thousand consecutive primary orthotopic liver transplants under FK 506: Survival and adverse events
22. Early trials with FK 506 as primary treatment in liver transplantation
23. Liver, kidney, and thoracic organ transplantation under FK 506
24. Chronic liver allograft rejection: A National Institute of Diabetes and Digestive and Kidney Diseases interinstitutional study analyzing the reliability of current criteria and proposal of an expanded definition
25. Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection
26. Patterns of graft rejection following liver transplantation
27. Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: Assessment of risk factors
28. Posttransplant B, non-A non-B, and cytomegalovirus hepatitis increase the risk of developing chronic rejection after liver transplantation
29. Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation
30. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation
31. Causes of graft loss following liver transplantation for chronic hepatitis C
32. Cytomegalovirus infection and donor/ recipient HLA antigens: Interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation
33. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
34. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts
35. Pathologic analysis of liver transplantation for primary biliary cirrhosis
36. Sex mismatch as a risk factor for chronic rejection of liver allografts
37. Recurrence of autoimmune hepatitis after liver transplantation
38. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation
39. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: Is chronic rejection part of the disease process?
40. Recurrence of primary sclerosing cholangitis following liver transplantation
41. Comparative long term evaluation of tacrolimus and cyclosporin in pediatric liver transplantation
42. Noncompliance after pediatric liver transplantation
43. Noncompliance in organ transplant recipients
44. Allograft rejection after liver transplantation for autoimmune liver diseases
45. Criteria for the histopathological classification of liver allograft rejection and their clinical relevance
46. Bile duct injury as a part of diagnostic criteria for liver allograft rejection
47. Is the use of marginal donors justified in liver transplantation? Analysis of results and proposal of modern criteria
48. Effect of donor age and sex on the outcome of liver transplantation
49. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: Long-term follow-up and evaluation of features for histopathological staging
50. Evidence for an immune response to HLA class I antigens in the vanishing-bile duct syndrome after liver transplantation
51. Influence of human leukocyte antigen matching on liver allograft survival and rejection: "The dualistic effect"
52. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome
53. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts
54. IgG donor-specific crossmatches are not associated with graft rejection or poor graft survival after liver transplantation. An assessment by cytotoxicity and flow cytometry